Analyst Price Targets — SLNO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 17, 2026 9:17 am | — | Wells Fargo | $53.00 | $52.57 | TheFly | Soleno Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo |
| March 4, 2026 11:41 am | Raghuram Selvaraju | H.C. Wainwright | $100.00 | $38.50 | StreetInsider | Soleno Therapeutics Inc. (SLNO) PT Lowered to $100 at H.C. Wainwright |
| January 20, 2026 11:19 am | Derek Archila | Wells Fargo | $114.00 | $42.48 | TheFly | Soleno Therapeutics price target raised to $114 from $106 at Wells Fargo |
| January 20, 2026 11:17 am | — | H.C. Wainwright | $120.00 | $42.48 | TheFly | Soleno Therapeutics price target raised to $120 from $110 at H.C. Wainwright |
| January 13, 2026 1:41 pm | — | Robert W. Baird | $107.00 | $40.14 | TheFly | Soleno Therapeutics price target lowered to $107 from $121 at Baird |
| January 12, 2026 6:52 pm | — | Wolfe Research | $60.00 | $41.89 | TheFly | Soleno Therapeutics price target lowered to $60 from $75 at Wolfe Research |
| November 5, 2025 11:26 am | Derek Archila | Wells Fargo | $106.00 | $63.85 | TheFly | Soleno Therapeutics price target lowered to $106 from $123 at Wells Fargo |
| October 7, 2025 8:48 am | — | Goldman Sachs | $125.00 | $58.45 | TheFly | Soleno Therapeutics initiated with a Buy at Goldman Sachs |
| July 11, 2025 11:18 am | Brian Skorney | Robert W. Baird | $121.00 | $81.57 | TheFly | Soleno Therapeutics price target raised to $121 from $105 at Baird |
| March 28, 2025 11:06 am | Debjit Chattopadhyay | Guggenheim | $81.00 | $70.22 | TheFly | Soleno Therapeutics price target raised to $81 from $70 at Guggenheim |
Latest News for SLNO
New York, New York--(Newsfile Corp. - May 5, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 and November 4, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline. SO WHAT: If you purchased Soleno common stock during the Class Period you may be entitled…
NEW YORK, May 05, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ: SLNO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone…
BALA CYNWYD, Pa. , May 05, 2026 (GLOBE NEWSWIRE) -- Brodsky and Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith. com) or Marc Ackerman (mackerman@brodskysmith. com) at 855-576-4847.
SAN FRANCISCO, May 5, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman reminds investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO) of the pending securities class action and the upcoming May 5, 2026 lead plaintiff deadline. The firm urges investors who purchased Soleno common stock between March 26, 2025, and November 4, 2025 (the "Class Period"), and suffered significant losses to submit…
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SLNO.
U.S. House Trading
No House trades found for SLNO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.